Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression.
Contrast enhancement
Functional magnetic resonance imaging
Gadoxetic acid
Primary sclerosing cholangitis
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
15
06
2020
accepted:
30
08
2020
revised:
20
08
2020
pubmed:
13
9
2020
medline:
22
6
2021
entrez:
12
9
2020
Statut:
ppublish
Résumé
To investigate the added value of gadoxetic acid-enhanced MRI in monitoring liver function and disease progression in patients with primary sclerosing cholangitis (PSC). We retrospectively identified 104 consecutive patients (75 males; mean age 41.98 ± 12.5 years) with confirmed diagnosis of PSC who underwent 227 gadoxetic acid-enhanced MRI examinations between January 2008 and May 2019. Relative enhancement (RE) of the liver was correlated with the results of liver function tests (LFTs), scoring models (Model for End-Stage Liver Disease (MELD) score, Mayo Risk Score (MRS), Amsterdam-Oxford model (AOM)), and qualitative MRI findings. In addition, results were analyzed separately for excretory MRI examinations (n = 164) and nonexcretory examinations (n = 63) depending on excretion of gadoxetic acid into the common bile duct in the hepatobiliary phase (HBP). There was a significant correlation of RE with MRS (r = - 0.652), MELD score (r = - 0.474), AOM (r = - 0.468), and LFTs (P < 0.001). RE and albumin were significantly higher in the excretory group whereas scoring models, bilirubin, aspartate aminotransferase, alkaline phosphatase, and international normalized ratio were lower (P < 0.001). RE was lower in segments with absent HBP gadoxetic acid excretion into dilated bile ducts, reduced HBP parenchymal enhancement, atrophy, T2 hyperintensity, and bile duct abnormalities (P < 0.001). Relative enhancement of the liver in gadoxetic acid-enhanced MRI can be used to evaluate global and regional liver function and monitor disease progression in patients with PSC. Hepatobiliary phase gadoxetic acid biliary excretion appears to be a reproducible qualitative parameter for evaluating disease severity that can be easily integrated into routine clinical practice.
Identifiants
pubmed: 32918576
doi: 10.1007/s00261-020-02731-z
pii: 10.1007/s00261-020-02731-z
pmc: PMC8257540
doi:
Substances chimiques
Contrast Media
0
gadolinium ethoxybenzyl DTPA
0
Gadolinium DTPA
K2I13DR72L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
979-991Commentaires et corrections
Type : ErratumIn
Références
R. Chapman, J. Fevery, A. Kalloo, D.M. Nagorney, K.M. Boberg, B. Shneider, G.J. Gores, D. American Association for the Study of Liver, Diagnosis and management of primary sclerosing cholangitis, Hepatology 51(2) (2010) 660-78. https://doi.org/10.1002/hep.23294 .
J.H. Tabibian, C.L. Bowlus, Primary sclerosing cholangitis: A review and update, Liver Res 1(4) (2017) 221-230. https://doi.org/10.1016/j.livres.2017.12.002 .
doi: 10.1016/j.livres.2017.12.002
pubmed: 29977644
pmcid: 6028044
T.H. Karlsen, T. Folseraas, D. Thorburn, M. Vesterhus, Primary sclerosing cholangitis - a comprehensive review, J Hepatol 67(6) (2017) 1298-1323. https://doi.org/10.1016/j.jhep.2017.07.022 .
doi: 10.1016/j.jhep.2017.07.022
pubmed: 28802875
J.C. Goet, A. Floreani, X. Verhelst, N. Cazzagon, L. Perini, W.J. Lammers, A.C. de Vries, A.J. van der Meer, H.R. van Buuren, B.E. Hansen, Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis, J Hepatol 71(5) (2019) 992-999. https://doi.org/10.1016/j.jhep.2019.06.012 .
doi: 10.1016/j.jhep.2019.06.012
pubmed: 31278949
H. Nilsson, L. Blomqvist, L. Douglas, A. Nordell, H. Jacobsson, K. Hagen, A. Bergquist, E. Jonas, Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis, J Magn Reson Imaging 39(4) (2014) 879-886. https://doi.org/10.1002/jmri.24250 .
doi: 10.1002/jmri.24250
pubmed: 24123427
S. Lemoinne, N. Cazzagon, S. El Mouhadi, P.J. Trivedi, A. Dohan, A. Kemgang, K. Ben Belkacem, C. Housset, Y. Chretien, C. Corpechot, G. Hirschfield, A. Floreani, R. Motta, B. Gallix, A. Barkun, J. Barkun, O. Chazouilleres, L. Arrive, Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis, Clin Gastroenterol Hepatol (2019). https://doi.org/10.1016/j.cgh.2019.03.013 .
E.M. de Vries, M. de Krijger, M. Farkkila, J. Arola, P. Schirmacher, D. Gotthardt, B. Goeppert, P.J. Trivedi, G.M. Hirschfield, H. Ytting, B. Vainer, H.R. Buuren, K. Biermann, M.H. Harms, O. Chazouilleres, D. Wendum, A.D. Kemgang, R.W. Chapman, L.M. Wang, K.D. Williamson, A.S. Gouw, V. Paradis, C. Sempoux, U. Beuers, S.G. Hubscher, J. Verheij, C.Y. Ponsioen, Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study, Hepatology 65(3) (2017) 907-919. https://doi.org/10.1002/hep.28963 .
doi: 10.1002/hep.28963
pubmed: 27880989
W.R. Kim, T.M. Therneau, R.H. Wiesner, J.J. Poterucha, J.T. Benson, M. Malinchoc, N.F. LaRusso, K.D. Lindor, E.R. Dickson, A revised natural history model for primary sclerosing cholangitis, Mayo Clin Proc 75(7) (2000) 688-94. https://doi.org/10.4065/75.7.688 .
doi: 10.4065/75.7.688
pubmed: 10907383
P.J. Trivedi, Risk stratification in primary sclerosing cholangitis: It’s time to move on from replicating imperfection and break the glass ceiling, J Hepatol 71(5) (2019) 867-870. https://doi.org/10.1016/j.jhep.2019.08.013 .
doi: 10.1016/j.jhep.2019.08.013
pubmed: 31515045
E. Christensen, Prognostic models including the Child–Pugh, MELD and Mayo risk scores—where are we and where should we go?, J Hepatol 41(2) (2004) 344-350. https://doi.org/10.1016/j.jhep.2004.06.005 .
doi: 10.1016/j.jhep.2004.06.005
pubmed: 15288486
C.Y. Ponsioen, S.M. Vrouenraets, W. Prawirodirdjo, R. Rajaram, E.A. Rauws, C.J. Mulder, J.B. Reitsma, S.H. Heisterkamp, G.N. Tytgat, Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population, Gut 51(4) (2002) 562-6. https://doi.org/10.1136/gut.51.4.562 .
doi: 10.1136/gut.51.4.562
pubmed: 12235081
pmcid: 1773389
C.Y. Ponsioen, J.B. Reitsma, K.M. Boberg, L. Aabakken, E.A.J. Rauws, E. Schrumpf, Validation of a cholangiographic prognostic model in primary sclerosing cholangitis, Endoscopy 42(09) (2010) 742-747. https://doi.org/10.1055/s-0030-1255527 .
doi: 10.1055/s-0030-1255527
pubmed: 20623444
P.S. Kamath, R.H. Wiesner, M. Malinchoc, W. Kremers, T.M. Therneau, C.L. Kosberg, G. D’Amico, E.R. Dickson, W.R. Kim, A model to predict survival in patients with end-stage liver disease, Hepatology 33(2) (2001) 464-70. https://doi.org/10.1053/jhep.2001.22172 .
doi: 10.1053/jhep.2001.22172
pubmed: 11172350
. Said, J. Williams, J. Holden, P. Remington, R. Gangnon, A. Musat, M.R. Lucey, Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease, J Hepatol 40(6) (2004) 897-903. https://doi.org/10.1016/j.jhep.2004.02.010 .
doi: 10.1016/j.jhep.2004.02.010
pubmed: 15158328
F. Botta, E. Giannini, P. Romagnoli, A. Fasoli, F. Malfatti, B. Chiarbonello, E. Testa, D. Risso, G. Colla, R. Testa, MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study, Gut 52(1) (2003) 134-139. https://doi.org/10.1136/gut.52.1.134 .
doi: 10.1136/gut.52.1.134
pubmed: 12477775
pmcid: 1773509
E.M. de Vries, J. Wang, K.D. Williamson, M.M. Leeflang, K. Boonstra, R.K. Weersma, U. Beuers, R.W. Chapman, R.B. Geskus, C.Y. Ponsioen, A novel prognostic model for transplant-free survival in primary sclerosing cholangitis, Gut 67(10) (2018) 1864-1869. https://doi.org/10.1136/gutjnl-2016-313681 .
doi: 10.1136/gutjnl-2016-313681
pubmed: 28739581
L. Aabakken, T.H. Karlsen, J. Albert, M. Arvanitakis, O. Chazouilleres, J.-M. Dumonceau, M. Färkkilä, P. Fickert, G.M. Hirschfield, A. Laghi, M. Marzioni, M. Fernandez, S.P. Pereira, J. Pohl, J.-W. Poley, C.Y. Ponsioen, C. Schramm, F. Swahn, A. Tringali, C. Hassan, Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline, J Hepatol 66(6) (2017) 1265-1281. https://doi.org/10.1016/j.jhep.2017.02.013 .
doi: 10.1016/j.jhep.2017.02.013
N. Cazzagon, O. Chazouillères, C. Corpechot, S. El Mouhadi, E. Chambenois, B. Desaint, U. Chaput, S. Lemoinne, L. Arrivé, Predictive criteria of response to endoscopic treatment for severe strictures in primary sclerosing cholangitis, Clin Res Hepatol Gastroenterol 43(4) (2019) 387-394. https://doi.org/10.1016/j.clinre.2019.01.003 .
doi: 10.1016/j.clinre.2019.01.003
pubmed: 30772328
H. Hinrichs, J.B. Hinrichs, M. Gutberlet, H. Lenzen, H.J. Raatschen, F. Wacker, K.I. Ringe, Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC), Eur Radiol 26(4) (2016) 1116-24. https://doi.org/10.1007/s00330-015-3913-y .
doi: 10.1007/s00330-015-3913-y
pubmed: 26205638
C. Schramm, J. Eaton, K.I. Ringe, S. Venkatesh, J. Yamamura, M.R.I.w.g.o.t. IPSCSG, Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group, Hepatology (Baltimore, Md.) 66(5) (2017) 1675-1688. https://doi.org/10.1002/hep.29293 .
K.I. Ringe, J. Hinrichs, E.M. Merkle, T.J. Weismüller, F. Wacker, B.C. Meyer, Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion, J Magn Reson Imaging 40(1) (2014) 106-12. https://doi.org/10.1002/jmri.24381 .
doi: 10.1002/jmri.24381
pubmed: 24923477
L. European Association for the Study of the, EASL Clinical Practice Guidelines: management of cholestatic liver diseases, J Hepatol 51(2) (2009) 237-267. https://doi.org/10.1016/j.jhep.2009.04.009 .
R. Nolz, U. Asenbaum, M. Schoder, A. Wibmer, H. Einspieler, A.M. Prusa, M. Peck-Radosavljevic, A. Ba-Ssalamah, Diagnostic workup of primary sclerosing cholangitis: the benefit of adding gadoxetic acid-enhanced T1-weighted magnetic resonance cholangiography to conventional T2-weighted magnetic resonance cholangiography, Clin Radiol 69(5) (2014) 499-508. https://doi.org/10.1016/j.crad.2013.12.008 .
doi: 10.1016/j.crad.2013.12.008
pubmed: 24630133
E.A. Selvaraj, E.L. Culver, H. Bungay, A. Bailey, R.W. Chapman, M. Pavlides, Evolving role of magnetic resonance techniques in primary sclerosing cholangitis, World J Gastroenterol 25(6) (2019) 644-658. https://doi.org/10.3748/wjg.v25.i6.644 .
doi: 10.3748/wjg.v25.i6.644
pubmed: 30783369
pmcid: 6378540
T. Watanabe, K. Hirano, M. Tada, H. Isayama, S. Mizuno, T. Arizumi, N. Toda, Y. Sugawara, N. Kokudo, K. Koike, Short-term prognostic factors for primary sclerosing cholangitis, J Hepatobiliary Pancreat Sci 22(6) (2015) 486-490. https://doi.org/10.1002/jhbp.238 .
doi: 10.1002/jhbp.238
pubmed: 25826613
J. Schulze, H. Lenzen, J.B. Hinrichs, B. Ringe, M.P. Manns, F. Wacker, K.I. Ringe, An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis, Clin Gastroenterol Hepatol 17(1) (2019) 192-199.e3. https://doi.org/10.1016/j.cgh.2018.05.011 .
doi: 10.1016/j.cgh.2018.05.011
pubmed: 29775791
N. Bastati, L. Beer, M. Mandorfer, S. Poetter-Lang, D. Tamandl, Y. Bican, M.C. Elmer, H. Einspieler, G. Semmler, B. Simbrunner, M. Weber, J.C. Hodge, F. Vernuccio, C. Sirlin, T. Reiberger, A. Ba-Ssalamah, Does the Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?, Radiology 294(1) (2020) 98-107. https://doi.org/10.1148/radiol.2019190734 .
doi: 10.1148/radiol.2019190734
pubmed: 31743083
S. Keller, S.K. Venkatesh, M. Avanesov, J.M. Weinrich, R. Zenouzi, C. Schramm, G. Adam, J. Yamamura, Gadolinium-based relative contrast enhancement in primary sclerosing cholangitis: additional benefit for clinicians?, Clin Radiol 73(7) (2018) 677.e1-677.e6. https://doi.org/10.1016/j.crad.2018.02.010 .